UniQure (NASDAQ: QURE) shares stabilized in premarket trading Thursday after a massive 78.4% surge the prior session, following the U.S. Food and Drug Administration's indication that early-stage clinical data could support an accelerated-approval submission for its experimental Huntington's disease gene therapy, AMT-130.
The Netherlands-based gene therapy specialist closed Wednesday at $48.16, up sharply from $26.99, as investors cheered the regulatory green light. The company announced it plans to file a Biologics License Application (BLA) with the FDA in the third quarter of 2026, seeking U.S. marketing approval for the treatment.
Regulatory Shift
The FDA's move marks a significant shift from earlier this year, when the agency had reportedly pushed for a new trial involving a sham surgical procedure. Because AMT-130 is administered directly into the brain, such a requirement raised ethical concerns. Now, the FDA is considering a control group receiving standard-of-care therapy instead, according to uniQure.
The FDA told uniQure that three-year follow-up data from its Phase I/II trial could serve as the basis for an accelerated-approval BLA. This pathway allows the agency to clear drugs for serious conditions based on data that are reasonably likely to predict clinical benefit, though confirmatory evidence is required post-approval.
Clinical Data and Pipeline
UniQure's U.S. Phase I/II trial enrolled 26 patients with early manifest Huntington's disease, while a European open-label study included 13 patients. Data released last year indicated a 75% reduction in disease progression among patients receiving the high dose of AMT-130. Huntington's disease is a genetic neurodegenerative disorder with no approved treatments that alter its course.
CEO Matt Kapusta stated that the FDA has agreed to assist uniQure in designing the necessary confirmatory trial. The company expects to receive formal meeting minutes within the next 30 days.
Market Context and Competition
Analysts view the FDA's stance as a sign of increased flexibility in rare disease regulation. Guggenheim's Debjit Chattopadhyay noted a growing recognition of the challenges inherent in rare-disease studies, while William Blair's Myles Minter described the regulator as appearing more open to alternative development paths.
UniQure is not alone in the Huntington's race. PTC Therapeutics and Novartis are advancing their oral candidate votoplam, with PTC reporting a 52% slowdown in disease progression in stage 2 patients at the 10 mg dose over 24 months. Novartis has initiated a global Phase 3 trial targeting approximately 770 patients.
Risks and Outlook
Despite the rally, risks remain. UniQure's risk disclosure notes that the FDA could ultimately deem the Phase I/II data insufficient for filing or accelerated approval. Additional patient data may also alter the three-year results. The stock's continued momentum hinges on regulatory follow-through and the successful completion of confirmatory studies.
Thursday marks the last full trading day before the Juneteenth holiday on Friday, June 19, when Nasdaq markets will be closed.
